Characteristics of patients treated
. | All patients (N = 256) . | Transplant (N = 147) . | No transplant (N = 109) . | P value . |
---|---|---|---|---|
Age at treatment, y, median (range) | 58 (18, 75) | 54 (18, 75) | 62 (21, 75) | < .001 |
D from diagnosis to initial treatment, median (range) | 5 (1, 155) | 5 (1, 155) | 6 (1, 28) | .23 |
D from initial treatment to transplant, median (range) | 118 (58, 621) | |||
Distance from hospital, median (range) | 29.5 (2.4, 882) | 27.4 (3.4, 882) | 33.8 (2.4, 174) | .12 |
Male sex | 131 (51%) | 72 (49%) | 59 (54%) | .45 |
Race | .027 | |||
White | 174 (68%) | 102 (70%) | 72 (66%) | |
Black | 67 (26%) | 32 (22%) | 35 (32%) | |
Other | 14 (6%) | 12 (8%) | 2 (2%) | |
Ethnicity | .22 | |||
Hispanic | 26 (10%) | 18 (12%) | 8 (7%) | |
Non-Hispanic | 230 (90%) | 129 (88%) | 101 (93%) | |
Diagnosis | .28 | |||
AML | 171 (67%) | 93 (63%) | 78 (26%) | |
ALL | 73 (28%) | 45 (31%) | 28 (71%) | |
MDS | 12 (5%) | 9 (6%) | 3 (3%) | |
Risk categories in patients with AML | .044 | |||
Intermediate risk | 51 (30%) | 34 (37%) | 17 (22%) | |
Poor risk | 120 (70%) | 59 (63%) | 61 (78%) | |
Risk categories in patients with ALL | .13 | |||
Standard risk | 14 (19%) | 6 (13%) | 8 (29%) | |
Poor risk | 59 (81%) | 39 (87%) | 20 (71%) | |
Y of initial treatment | .61 | |||
2016-2018 | 124 (48%) | 69 (47%) | 55 (50%) | |
2019-2021 | 132 (52%) | 78 (53%) | 54 (50%) | |
Number of survivors | 139 | 101 | 38 | |
Survivor follow-up from initial treatment (mo), median (range) | 35.0 (5.9, 76.8) | 36.3 (5.9, 76.8) | 28.3 (5.9, 73.6) | .45 |
. | All patients (N = 256) . | Transplant (N = 147) . | No transplant (N = 109) . | P value . |
---|---|---|---|---|
Age at treatment, y, median (range) | 58 (18, 75) | 54 (18, 75) | 62 (21, 75) | < .001 |
D from diagnosis to initial treatment, median (range) | 5 (1, 155) | 5 (1, 155) | 6 (1, 28) | .23 |
D from initial treatment to transplant, median (range) | 118 (58, 621) | |||
Distance from hospital, median (range) | 29.5 (2.4, 882) | 27.4 (3.4, 882) | 33.8 (2.4, 174) | .12 |
Male sex | 131 (51%) | 72 (49%) | 59 (54%) | .45 |
Race | .027 | |||
White | 174 (68%) | 102 (70%) | 72 (66%) | |
Black | 67 (26%) | 32 (22%) | 35 (32%) | |
Other | 14 (6%) | 12 (8%) | 2 (2%) | |
Ethnicity | .22 | |||
Hispanic | 26 (10%) | 18 (12%) | 8 (7%) | |
Non-Hispanic | 230 (90%) | 129 (88%) | 101 (93%) | |
Diagnosis | .28 | |||
AML | 171 (67%) | 93 (63%) | 78 (26%) | |
ALL | 73 (28%) | 45 (31%) | 28 (71%) | |
MDS | 12 (5%) | 9 (6%) | 3 (3%) | |
Risk categories in patients with AML | .044 | |||
Intermediate risk | 51 (30%) | 34 (37%) | 17 (22%) | |
Poor risk | 120 (70%) | 59 (63%) | 61 (78%) | |
Risk categories in patients with ALL | .13 | |||
Standard risk | 14 (19%) | 6 (13%) | 8 (29%) | |
Poor risk | 59 (81%) | 39 (87%) | 20 (71%) | |
Y of initial treatment | .61 | |||
2016-2018 | 124 (48%) | 69 (47%) | 55 (50%) | |
2019-2021 | 132 (52%) | 78 (53%) | 54 (50%) | |
Number of survivors | 139 | 101 | 38 | |
Survivor follow-up from initial treatment (mo), median (range) | 35.0 (5.9, 76.8) | 36.3 (5.9, 76.8) | 28.3 (5.9, 73.6) | .45 |